Lifestyle and Pharmacotherapy for Weight Loss in Preventing or Delaying Diabetes

Stephanie Price, Quynh Nhu Le, Nicole D. White

Research output: Contribution to journalReview article

Abstract

Preventing or delaying the conversion of prediabetes to overt diabetes can reduce mortality and morbidity rates, improve health-related quality of life, and reduce other comorbid complications associated with diabetes. Studies have shown that a modest weight loss is one strategy for preventing or delaying diabetes diagnosis. First-line therapy in preventing progression of prediabetes to overt diabetes is weight loss through lifestyle modifications; however, pharmacotherapy for weight loss may be initiated if lifestyle alone is ineffective. The purpose of this article is to describe the pharmacotherapeuptic options for weight loss that can be used in conjunction with lifestyle in the prevention or delay of diabetes in patients with prediabetes.

Original languageEnglish (US)
Pages (from-to)34-37
Number of pages4
JournalAmerican Journal of Lifestyle Medicine
Volume12
Issue number1
DOIs
StatePublished - Jan 1 2018

Fingerprint

Prediabetic State
Life Style
Weight Loss
Drug Therapy
Quality of Life
Morbidity
Mortality
Therapeutics

All Science Journal Classification (ASJC) codes

  • Medicine (miscellaneous)
  • Health Policy
  • Public Health, Environmental and Occupational Health

Cite this

Lifestyle and Pharmacotherapy for Weight Loss in Preventing or Delaying Diabetes. / Price, Stephanie; Le, Quynh Nhu; White, Nicole D.

In: American Journal of Lifestyle Medicine, Vol. 12, No. 1, 01.01.2018, p. 34-37.

Research output: Contribution to journalReview article

@article{31eba752b0be4546a85478de432227f3,
title = "Lifestyle and Pharmacotherapy for Weight Loss in Preventing or Delaying Diabetes",
abstract = "Preventing or delaying the conversion of prediabetes to overt diabetes can reduce mortality and morbidity rates, improve health-related quality of life, and reduce other comorbid complications associated with diabetes. Studies have shown that a modest weight loss is one strategy for preventing or delaying diabetes diagnosis. First-line therapy in preventing progression of prediabetes to overt diabetes is weight loss through lifestyle modifications; however, pharmacotherapy for weight loss may be initiated if lifestyle alone is ineffective. The purpose of this article is to describe the pharmacotherapeuptic options for weight loss that can be used in conjunction with lifestyle in the prevention or delay of diabetes in patients with prediabetes.",
author = "Stephanie Price and Le, {Quynh Nhu} and White, {Nicole D.}",
year = "2018",
month = "1",
day = "1",
doi = "10.1177/1559827617740825",
language = "English (US)",
volume = "12",
pages = "34--37",
journal = "American Journal of Lifestyle Medicine",
issn = "1559-8276",
publisher = "SAGE Publications Inc.",
number = "1",

}

TY - JOUR

T1 - Lifestyle and Pharmacotherapy for Weight Loss in Preventing or Delaying Diabetes

AU - Price, Stephanie

AU - Le, Quynh Nhu

AU - White, Nicole D.

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Preventing or delaying the conversion of prediabetes to overt diabetes can reduce mortality and morbidity rates, improve health-related quality of life, and reduce other comorbid complications associated with diabetes. Studies have shown that a modest weight loss is one strategy for preventing or delaying diabetes diagnosis. First-line therapy in preventing progression of prediabetes to overt diabetes is weight loss through lifestyle modifications; however, pharmacotherapy for weight loss may be initiated if lifestyle alone is ineffective. The purpose of this article is to describe the pharmacotherapeuptic options for weight loss that can be used in conjunction with lifestyle in the prevention or delay of diabetes in patients with prediabetes.

AB - Preventing or delaying the conversion of prediabetes to overt diabetes can reduce mortality and morbidity rates, improve health-related quality of life, and reduce other comorbid complications associated with diabetes. Studies have shown that a modest weight loss is one strategy for preventing or delaying diabetes diagnosis. First-line therapy in preventing progression of prediabetes to overt diabetes is weight loss through lifestyle modifications; however, pharmacotherapy for weight loss may be initiated if lifestyle alone is ineffective. The purpose of this article is to describe the pharmacotherapeuptic options for weight loss that can be used in conjunction with lifestyle in the prevention or delay of diabetes in patients with prediabetes.

UR - http://www.scopus.com/inward/record.url?scp=85040712772&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040712772&partnerID=8YFLogxK

U2 - 10.1177/1559827617740825

DO - 10.1177/1559827617740825

M3 - Review article

AN - SCOPUS:85040712772

VL - 12

SP - 34

EP - 37

JO - American Journal of Lifestyle Medicine

JF - American Journal of Lifestyle Medicine

SN - 1559-8276

IS - 1

ER -